On September 15, 2025, the official website of the National Medical Products Administration (NMPA) announced that the marketing authorization application for the self-developed Sabin-strain Inactivated Poliovirus Vaccine (Vero cell) (sIPV) by Beijing Minhai Biological Co., Ltd. had been approved (National Drug Approval No. S20250051).

This landmark achievement marks a crucial leap forward for China in the independent innovation and industrialization of poliovirus vaccines. It also demonstrates that Minhai Biological’s innovative capabilities have boosted the accessibility and affordability of IPV vaccines worldwide, embodying the global responsibility of Chinese vaccine manufacturers.

Dedicated Focus, Craftsmanship-Driven Customer Service

The production of inactivated poliovirus vaccines imposes extremely stringent quality control standards. In particular, the detection of Host Cell Residual DNA (HCD) serves as a critical procedure to guarantee vaccine safety and regulatory compliance.

HZSKBIO^® is honored to be a long-term supplier of professional reagents for Minhai Biological. Drawing on profound technical expertise in quality control for biological products, we provide sample pre-processing kits, Vero residual DNA detection kits, and the rHCDpurify pre-processing system for quality control throughout vaccine R&D and manufacturing. We will keep striving to deliver premium products and thoughtful services to all partners.

Reliable Supply Chains, Professional Expertise Safeguards Quality

HZSKBIO^® is committed to delivering one-stop quality control solutions for biopharmaceutical enterprises at home and abroad. Our product portfolio covers a wide range of fields, including host cell residual DNA/RNA detection, host cell protein residual detection, rapid microbial testing, and process impurity analysis. By supporting our key customer to bring this vaccine to market, we once again validate HZSKBIO^®’s leading technological edge and service proficiency in core vaccine quality control workflows.

We wish all domestic vaccine manufacturers continued success in launching more high-quality products, contributing China’s strength to global public health initiatives.